Amneal Pharmaceuticals Inc. saw its stock surge nearly 10.0% in pre-market trading to around $21 after the company reported a substantial second-quarter 2026 outperformance across core financial measures.
The Bridgewater, New Jersey-based biopharmaceutical firm posted revenue of $796.2 million, topping analyst projections of $768.2 million and marking 9.9% year-on-year growth. Adjusted earnings per share came in at $0.30, exceeding the consensus estimate of $0.23 by more than 30%.
Company executives described the quarter as "strong, broad-based," and said the solid results through the first half of the year gave them confidence to raise full-year 2026 guidance for a second time.
Key guidance updates included lifting the full-year revenue guidance midpoint to $3.15 billion from $3.1 billion. The company also set EBITDA guidance at a $765 million midpoint, which sits above analyst estimates of $748 million.
Management characterized the quarterly performance as "strong, broad-based."
Amneal highlighted the pending Kashiv transaction as an important development that would position biosimilars as a meaningful, enduring growth vertical for the company and further diversify its portfolio.
The earnings release arrived into a relatively constructive analyst environment. Goldman Sachs had reaffirmed a Buy rating on the stock the previous day, and UBS raised its price target to $23 from $19 in late June. Those analyst actions, combined with the quarterly beats and guidance raise, helped drive investor enthusiasm.
Amneal was among the first companies in its peer group to report results this earnings season, which meant there were limited comparable corporate read-throughs available. Nevertheless, positive sentiment in the pharmaceuticals segment had been building ahead of the print.
The broader market backdrop was also favorable. The NASDAQ was up 1.16% and the S&P 500 rose 0.58%, reflecting a risk-on tone that amplified market responses to company-specific positive news.
The mix of a multi-faceted earnings beat, a second consecutive upward revision to full-year guidance, and a supportive analyst community produced a strong catalyst for the sharp pre-market move. The stock is trading close to the top of its 52-week range, signaling a notable re-rating as investors respond to the company’s diversified business model and specialty pipeline momentum.
Summary
Amneal delivered better-than-expected Q2 results on revenue and adjusted EPS, raised full-year revenue and EBITDA guidance midpoints, and highlighted a pending biosimilars-related transaction while benefiting from positive analyst coverage and a favorable market tone.
Key details
- Q2 revenue: $796.2 million versus $768.2 million estimate (9.9% YoY growth).
- Adjusted EPS: $0.30 versus $0.23 consensus.
- Raised full-year revenue midpoint to $3.15 billion and EBITDA midpoint to $765 million; EBITDA midpoint above analyst estimate of $748 million.